NCT06886269View on ClinicalTrials.gov

A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 21, 2025

Primary Completion Date

May 17, 2025

Study Completion Date

May 17, 2025

Conditions
Pain
Interventions
DRUG

14C-VX-993

Solution for Oral Administration.

Trial Locations (1)

68502

Celerion - Lincoln, Lincoln

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT06886269 - A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose | Biotech Hunter | Biotech Hunter